Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT06893016
PHASE3
Evaluation of RAY1225 in Adult Participants Who Have Obesity or Are Overweight
Sponsor: Guangdong Raynovent Biotech Co., Ltd
View on ClinicalTrials.gov
Summary
The primary objective of this study is to demonstrate that RAY1225 is superior to placebo for percent change in body weight.
Official title: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study Evaluating the Safety, Tolerability, and Efficacy of RAY1225 in Participants Who Have Obesity or Are Overweight
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
640
Start Date
2025-06-15
Completion Date
2026-09-15
Last Updated
2025-07-17
Healthy Volunteers
No
Conditions
Interventions
DRUG
RAY1225
RAY1225 will be administered SC
DRUG
Placebo
Placebo will be administered SC.
Locations (1)
Peking University People's Hospital
Beijing, China